Recruiting A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma NCT07059299 Conditions Adenocarcinoma Of Esophagus, Digestive System Diseases, Digestive System Neoplasms, +11 more Locations Krankenhaus Nordwest GmbH Institut für Klinisch-Onkologische Forschung (IKF) — Frankfurt, Germany Hämatologisch-Onkologische Praxis Eppendorf (hope) — Hamburg, Germany Universitätsklinikum Leipzig — Leipzig, Germany Klinikum rechts der Isar München der TU München — München, Germany View Trial Details
